Amarin Corp (NASDAQ:AMRN) shares are trading higher on Wednesday after Piper Sandler initiated coverage on the company's stock with an Overweight rating and announced a $21 price target.

Amarin is a biopharmaceutical company. It is focused on the commercialization and development of therapeutics to improve cardiovascular health. Its products include Vascepa.

Amarin shares were trading up 6.59% at $7.12 on Wednesday during the time of publication. The stock has a 52-week high of $26.12 and a 52-week low of $3.95.

Related Links:

Verastem Shares Response Rate From COPIKTRA Data

FDA Approves Edesa's Dermatitis Treatment Study, Shares Up More Than 100%